Breaking News

Cobra Biologics to Manufacture Plasmids for COVID-19 Vax Trial

Collaboration will ensure GMP production of material for Phase I clinical trial of Scancell’s DNA vaccine against SARS-CoV-2.

By: Contract Pharma

Contract Pharma Staff

Cobra Biologics, part of the Cognate BioServices family, and Scancell Holdings plc, a developer of immunotherapies for the treatment of cancer and infectious disease, have entered into a collaboration for Cobra to manufacture Scancell’s COVID-19 vaccine. The agreement covers Good Manufacturing Practice (GMP) production of plasmid DNA needed to generate the DNA vaccine, against SARS-CoV-2, for use in a Phase 1 clinical trial in 2021 (COVIDITY). The project is funded by an Innovate UK grant awarde...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters